Table.
Clinical trials of PARP1 inhibitors. Data were borrowed from reviews [42, 43]
| Name | Therapy | Tumors | CT phase |
|---|---|---|---|
| Rucaparib AG014699 | Monotherapy | BRCA mutant lung cancer, ovarian cancer | 2 |
| Rucaparib | +temozolomide | Solid tumors, melanoma | 2 |
| Rucaparib | +carboplatin | Solid tumors | 1 |
| Olaparib | Monotherapy | Solid tumors, BRCA, TNBC/HGSOC carriers | 2 |
| Olaparib | +topotecan | Solid tumors | 1 |
| Olaparib | +dacarbazine | Solid tumors | 1 |
| Olaparib | +bevacizumab | Solid tumors | 1 |
| Olaparib | +paclitaxel | Ovarian Cancer | 2 |
| Olaparib | +paclitaxel | Stomach cancer | 2 |
| Olaparib | +cisplatin | Solid tumors | 1 |
| Veliparib ABT-888 | Monotherapy | Solid tumors | 1 |
| Veliparib | +topotecan | Solid tumors | 1 |
| Veliparib | +carboplatin | Solid tumors | 1 |
| Veliparib | +temozolomide | Solid tumors, liver tumors, prostate cancer | 2 |
| Veliparib | +cyclophosphamide | Solid tumors and lymphomas | 2 |
| INO-1001 | +temozolomide | Melanoma | 1 |
| MK4827 | Monotherapy | Solid tumors and lymphoma | 2 |
| MK4827 | +temozolomide | Ovarian cancer/glioblastoma | 1 |
| MK4827 | +doxorubicin | Ovarian cancer/glioblastoma | 1 |
| CEP-9722 | Monotherapy | Solid tumors | 1 |
| CEP-9722 | +temozolomide | Lymphomas | 1 |
| BMN-673 | Monotherapy | Solid tumors | 1 |
| Iniparib (BSI-201) |
+gemcitabine +carboplatin |
mTNBC | 2 |
| Iniparib |
+gemcitabine +cisplatin |
Lung cancer | 2 |
| Iniparib |
+gemcitabine +carboplatin |
mTNBC | 3 |